{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:36Z","timestamp":1792177716279,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-01897-9","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T04:02:07Z","timestamp":1707192127000},"page":"1077-1084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study"],"prefix":"10.1093","volume":"37","author":[{"given":"Eleonora","family":"Riccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"D\u2019Ercole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hamzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Buonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"1897_CR1","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD et al (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156\u20131162","journal-title":"Arch Intern Med"},{"key":"1897_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/IJNRD.S326464","volume":"15","author":"A Sarnowski","year":"2022","unstructured":"Sarnowski A, Gama RM, Dawson A et al (2022) Hyperkalemia in chronic kidney disease: links, risks and management. Int J Nephrol Renovasc Dis 15:215\u2013228","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"1897_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","volume":"97","author":"CM Clase","year":"2020","unstructured":"Clase CM, CarreroJJ EDH et al (2020) Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kid Kidney Int 97:42\u201361","journal-title":"Kid Kidney Int"},{"issue":"1","key":"1897_CR4","first-page":"35","volume":"12","author":"NL Lariv\u00e9e","year":"2023","unstructured":"Lariv\u00e9e NL, Michaud JB, More KM et al (2023) Hyperkalemia: prevalence. Predict Emerg Treat Cardiol Ther 12(1):35\u201363","journal-title":"Predict Emerg Treat Cardiol Ther"},{"key":"1897_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G et al (1996) The Angiotensin converting-enzyme inhibition in progressive renal insufficiency study group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Eng J Med 334:939\u2013945","journal-title":"N Eng J Med"},{"key":"1897_CR6","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici In Nefrologia)","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici In Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857\u20131863","journal-title":"Lancet"},{"key":"1897_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.kint.2018.12.025","volume":"95","author":"AK Cheung","year":"2019","unstructured":"Cheung AK, Chang TI, Cushman WC et al (2019) Blood pressure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 95:1027\u20131036","journal-title":"Kidney Int"},{"key":"1897_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/kisup.2012.46","volume":"2","author":"Kidney Disease Improving Global Outcome (KDIGO) Working Group","year":"2012","unstructured":"Kidney Disease Improving Global Outcome (KDIGO) Working Group (2012) KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2:337\u2013414","journal-title":"Kidney Int"},{"key":"1897_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","volume":"62","author":"SJ Taler","year":"2013","unstructured":"Taler SJ, Agarwal R, Bakris GL et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 62:201\u2013213","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"1897_CR10","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.3390\/jcm11206184","volume":"11","author":"I Capuano","year":"2022","unstructured":"Capuano I, Buonanno P, Riccio E et al (2022) Randomized controlled trials on renin angiotensin aldosterone system inhibitors in chronic kidney disease stages 3\u20135: are they robust? a fragility index analysis. J Clin Med 11(20):6184","journal-title":"J Clin Med"},{"key":"1897_CR11","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE et al (2015) Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 21:S212-220","journal-title":"Am J Manag Care"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","volume":"34","author":"T Yildirim","year":"2012","unstructured":"Yildirim T, Arici M, Piskinpasa S et al (2012) Major barriers against renin\u2013angiotensin\u2013aldosterone system blocker use in chronic kidney disease stages 3\u20135 in clinical practice: a safety concern? Ren Fail 34:1095\u20131099","journal-title":"Ren Fail"},{"key":"1897_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000485645","volume":"138","author":"PA McCullogh","year":"2018","unstructured":"McCullogh PA, Rangaswami J (2018) Real or perceived: hyperkalemia is a major deterrent for renin-angiotensin aldosterone system inhibition in heart failure. Nephron 138:173\u2013175","journal-title":"Nephron"},{"key":"1897_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.824095","volume":"9","author":"E Riccio","year":"2022","unstructured":"Riccio E, Capuano I, Buonanno P et al (2022) RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study. Front Cardiovasc Med 9:824095","journal-title":"Front Cardiovasc Med"},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"BF Palmer","year":"2004","unstructured":"Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin\u2013angiotensin\u2013aldosterone system. N Engl J Med 351:585\u2013592","journal-title":"N Engl J Med"},{"key":"1897_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"21","author":"RH Sterns","year":"2010","unstructured":"Sterns RH, Rojas M, Bernstein P, Chennupati S (2010) Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 21:733\u2013735","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1897_CR17","doi-asserted-by":"publisher","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Z Harel","year":"2013","unstructured":"Harel Z, Harel S, Shah PS et al (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 126(3):264.e9-264.e24","journal-title":"Am J Med"},{"key":"1897_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/fca.11.71","volume":"8","author":"JM Buysse","year":"2012","unstructured":"Buysse JM, Huang IZ, Pitt B (2012) PEARL HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Futur Cardiol 8:17\u201328","journal-title":"Futur Cardiol"},{"issue":"10208","key":"1897_CR19","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A (2019) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394(10208):1540\u20131550","journal-title":"Lancet"},{"issue":"11","key":"1897_CR20","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1093\/nutrit\/nuac026","volume":"80","author":"DE St-Jules","year":"2022","unstructured":"St-Jules DE, Fouque D (2022) Etiology-based dietary approach for managing hyperkalemia in people with chronic kidney disease. Nutr Rev 80(11):2198\u20132205","journal-title":"Nutr Rev"},{"issue":"10","key":"1897_CR21","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/jcph.713","volume":"56","author":"PH Hinderling","year":"2016","unstructured":"Hinderling PH (2016) The pharmacokinetics of potassium in humans is unusual. J Clin Pharmacol 56(10):1212\u20131220","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1897_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/00325481.2019.1706920","volume":"132","author":"CP Kovesdy","year":"2020","unstructured":"Kovesdy CP, Gosmanova EO, Woods SD et al (2020) Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med 132(2):176\u2013183","journal-title":"Postgrad Med"},{"issue":"1","key":"1897_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/ckj\/sfac209","volume":"16","author":"R Pecoits-Filho","year":"2022","unstructured":"Pecoits-Filho R, McCullough K, Muenz D et al (2022) Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany. Clin Kidney J 16(1):176\u2013183","journal-title":"Clin Kidney J"},{"key":"1897_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"issue":"2","key":"1897_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR et al (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial AMETHYST-DN. Invest JAMA 314(2):151\u2013161","journal-title":"Invest JAMA"},{"issue":"3","key":"1897_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, OPAL-HK Investigators et al (2015) Investigators patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372(3):211\u2013221","journal-title":"N Engl J Med"},{"key":"1897_CR27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Bakris GL, Bushinsky DA et al (2015) Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 17:1057\u20131065","journal-title":"Eur J Heart Fail"},{"key":"1897_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ehf2.12292","volume":"5","author":"B Pitt","year":"2018","unstructured":"Pitt B, Bakris GL, Weir MR et al (2018) Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail 5:592","journal-title":"ESC Heart Fail"},{"key":"1897_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/aje\/kwv446","volume":"184","author":"RL Drieling","year":"2016","unstructured":"Drieling RL, LaCroix AZ, Beresford SA et al (2016) Validity of self-reported medication use compared with pharmacy records in a cohort of older women: findings from the women\u2019s health initiative. Am J Epidemiol 184:233\u2013238","journal-title":"Am J Epidemiol"},{"key":"1897_CR30","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jch.13563","volume":"21","author":"R Pecoits-Filho","year":"2019","unstructured":"Pecoits-Filho R, Fliser D, Tu C et al (2019) Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. J Clin Hypertens (Greenwich) 21:991\u20131001","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1897_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/PPA.S54922","volume":"8","author":"M Sabbatini","year":"2014","unstructured":"Sabbatini M, Garofalo G, Borrelli S et al (2014) Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence 8:73\u201381","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"1897_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41430-018-0154-6","volume":"73","author":"RPM te Dorsthorst","year":"2019","unstructured":"te Dorsthorst RPM, Hendrikse J, Vervoorn MT et al (2019) Review of case reports on hyperkalemia induced by dietary intake: not restricted to chronic kidney disease patients. Eur J Clin Nutr 73(1):38\u201345","journal-title":"Eur J Clin Nutr"},{"issue":"11","key":"1897_CR33","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1093\/ndt\/gfaa232","volume":"36","author":"CI Ramos","year":"2021","unstructured":"Ramos CI, Gonz\u00e1lez-Ortiz A, Espinosa-Cuevas A et al (2021) Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? Nephrol Dial Transplant 36(11):2049\u20132057","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-01897-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:00Z","timestamp":1777564440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/4\/1077\/8306785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-01897-9","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institute and regional research committee and with the 1964 Helsinki declaration and its later amendments of comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"All participants signed written informed consent for participation in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}